|
1
|
Parkin DM, Bray FI and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer. 37
(Suppl 8):S4–S66. 2001.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bilfinger T, Keresztes R, Albano D and
Nemesure B: Five-year survival among stage IIIA lung cancer
patients receiving two different treatment modalities. Med Sci
Monit. 22:2589–2594. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Minna JD, Roth JA and Gazdar AF: Focus on
lung cancer. Cancer Cell. 1:49–52. 2002.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Yang J, Zhang Z, Chen S, Dou W, Xie R and
Gao J: miR-654-3p predicts the prognosis of hepatocellular
carcinoma and inhibits the proliferation, migration, and invasion
of cancer cells. Cancer Biomark. 28:73–79. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wang M, Qiu R, Gong Z, Zhao X, Wang T,
Zhou L, Lu W, Shen B, Zhu W and Xu W: miR-188-5p emerges as an
oncomiRNA to promote gastric cancer cell proliferation and
migration via upregulation of SALL4. J Cell Biochem.
120:15027–15037. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tang X, Ding Y, Wang X, Wang X, Zhao L and
Bi H: miR-650 promotes non-small cell lung cancer cell
proliferation and invasion by targeting ING4 through
Wnt-1/β-catenin pathway. Oncol Lett. 18:4621–4628. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Luo J, Pan J, Jin Y, Li M and Chen M:
miR-195-5p Inhibits proliferation and induces apoptosis of
non-small cell lung cancer cells by targeting CEP55. Onco Targets
Ther. 12:11465–11474. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhong K, Chen K, Han L and Li B:
MicroRNA-30b/c inhibits non-small cell lung cancer cell
proliferation by targeting Rab18. BMC Cancer.
14(703)2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hu Y, Wang L, Gu J, Qu K and Wang Y:
Identification of microRNA differentially expressed in three
subtypes of non-small cell lung cancer and in silico functional
analysis. Oncotarget. 8:74554–74566. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang J, Guo XJ, Ding YM and Jiang JX:
miR-1181 inhibits invasion and proliferation via STAT3 in
pancreatic cancer. World J Gastroenterol. 23:1594–1601.
2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang HY, Li JH, Li G and Wang SR:
Activation of ARK5/miR-1181/HOXA10 axis promotes
epithelial-mesenchymal transition in ovarian cancer. Oncol Rep.
34:1193–1202. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Song Z, Yu Z, Chen L, Zhou Z, Zou Q and
Liu Y: MicroRNA-1181 supports the growth of hepatocellular
carcinoma by repressing AXIN1. Biomed Pharmacother.
119(109397)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cai Z, Li J, Zhuang Q, Zhang X, Yuan A,
Shen L, Kang K, Qu B, Tang Y, Pu J, et al: MiR-125a-5p ameliorates
monocrotaline-induced pulmonary arterial hypertension by targeting
the TGF-β1 and IL-6/STAT3 signaling pathways. Exp Mol Med. 50:1–11.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Benderska N, Dittrich AL, Knaup S, Rau TT,
Neufert C, Wach S, Fahlbusch FB, Rauh M, Wirtz RM, Agaimy A, et al:
miRNA-26b overexpression in ulcerative colitis-associated
carcinogenesis. Inflamm Bowel Dis. 21:2039–2051. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pao W: New approaches to targeted therapy
in lung cancer. Proc Am Thorac Soc. 9:72–73. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liu CG, Calin GA, Meloon B, Gamliel N,
Sevignani C, Ferracin M, Dumitru CD, Shimizu M, Zupo S, Dono M, et
al: An oligonucleotide microchip for genome-wide microRNA profiling
in human and mouse tissues. Proc Natl Acad Sci USA. 101:9740–9744.
2004.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261.
2006.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yoon JS, Kim G, Lee YR, Park SY, Tak WY,
Kweon YO, Park JG, Lee HW, Han YS, Ha HT, et al: Clinical
significance of microRNA-21 expression in disease progression of
patients with hepatocellular carcinoma. Biomark Med. 12:1105–1114.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang D, Lu G, Shao Y and Xu D: MiR-182
promotes prostate cancer progression through activating
Wnt/β-catenin signal pathway. Biomed Pharmacother. 99:334–339.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Feng Y, Yang C, Hu D, Wang X and Liu X:
miR-675 promotes disease progression of non-small cell lung cancer
via activating NF-κB signaling pathway. Cell Mol Biol
(Noisy-le-grand). 63:7–10. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Liu H, Ma Y, Liu C, Li P and Yu T: Reduced
miR-125a-5p level in non-small-cell lung cancer is associated with
tumour progression. Open Biol. 8(180118)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shao C, Yang F, Qin Z, Jing X, Shu Y and
Shen H: The value of miR-155 as a biomarker for the diagnosis and
prognosis of lung cancer: A systematic review with meta-analysis.
BMC Cancer. 19(1103)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
An JX, Ma ZS, Ma MH, Shao S, Cao FL and
Dai DQ: MiR-1236-3p serves as a new diagnostic and prognostic
biomarker for gastric cancer. Cancer Biomark. 25:127–132.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Peng X, Pan X, Liu K, Zhang C, Zhao L, Li
H, Guan X, Xu W, Xu J, Zhang F and Lai Y: miR-142-3p as a novel
biomarker for predicting poor prognosis in renal cell carcinoma
patients after surgery. Int J Biol Markers. 34:302–308.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang Y, Jiang F, Wang J, Fu Y, Li Y and Li
F: MiR-519a functions as a tumor suppressor and is negatively
associated with poor prognosis of non-small cell lung cancer.
Cancer Biomark. 28:121–128. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhang Y and Xu H: Serum exosomal miR-378
upregulation is associated with poor prognosis in non-small-cell
lung cancer patients. J Clin Lab Anal. 34(e23237)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Fan L, Wang J, Cao Q, Ding X and Li B:
Aberrant miR-1246 expression promotes radioresistance in non-small
cell lung cancer: A potential prognostic biomarker and radiotherapy
sensitization target. Am J Cancer Res. 10:314–335. 2020.PubMed/NCBI
|
|
32
|
Jiang J, Li Z, Yu C, Chen M, Tian S and
Sun C: MiR-1181 inhibits stem cell-like phenotypes and suppresses
SOX2 and STAT3 in human pancreatic cancer. Cancer Lett.
356:962–970. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ning L, Zhang M, Zhu Q, Hao F, Shen W and
Chen D: miR-25-3p inhibition impairs tumorigenesis and invasion in
gastric cancer cells in vitro and in vivo. Bioengineered. 11:81–90.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Soheilyfar S, Velashjerdi Z, Sayed
Hajizadeh Y, Fathi Maroufi N, Amini Z, Khorrami A, Haj Azimian S,
Isazadeh A, Taefehshokr S and Taefehshokr N: In vivo and in vitro
impact of miR-31 and miR-143 on the suppression of metastasis and
invasion in breast cancer. J BUON. 23:1290–1296. 2018.PubMed/NCBI
|
